R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation

RIDA^®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA^®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRpgene in all currently known variants and mutations of the COVID 19 virus.

Only validated products, or products on the temporary protocol, can be sold in the UK after 31 October 2021. Jason Baggaley, Sales Manager of R-Biopharm for Great Britain, commented: “We are proud that our RIDA^®GENE Flu & SARS-CoV-2 test was approved and added to the CTDA register and our customers will continue to be able to distinguish between the flu and an infection with the Corona virus.“

 Press contact:

Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com 
https://r-biopharm.com/news-press

R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany

Tel.: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40

Email: s.feiler@r-biopharm.de